Wuxi biologics recognized as industry and regional esg top-rated company by morningstar sustainalytics for fifth consecutive year

Ranked among the top 1% of companies assessed in the pharmaceutical industry recognized as a leader in green crdmo, driving innovation for a healthier future committed to creating long-term value for all stakeholders shanghai , feb. 10, 2025 /prnewswire/ -- wuxi biologics ("wuxi bio") (2269.hk), a leading global contract research, development, and manufacturing organization (crdmo), today announced it has been recognized as a 2025 industry and regional esg top-rated company by morningstar sustainalytics, marking the fifth consecutive year the company has scored among the highest in esg risk ratings. sustainalytics , a leading esg data, research, and ratings firm, supports global investors with the development and implementation of responsible investment strategies.
MORN Ratings Summary
MORN Quant Ranking